Targeted nanotherapy for induction of therapeutic immune responses

Trends in Molecular Medicine

Volumn 18, Issue 2, 2012, Pages 72-80

  Metcalfe, Su M ^a   Fahmy, Tarek M ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Yale University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1 INTERFERON; BIOMATERIAL; CYTOKINE; HEPATITIS C VACCINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MYCOPHENOLIC ACID; NANOMATERIAL; NANOPARTICLE; POLYLACTIC ACID; RAPAMYCIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FOXP3; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BIOCOMPATIBILITY; BIODEGRADABILITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DEGENERATIVE DISEASE; DENDRITIC CELL; DENGUE; DISEASE TRANSMISSION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; EPIGENETICS; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; LIPOSOMAL DELIVERY; MICROENVIRONMENT; MOLECULAR DYNAMICS; MOLECULAR THERAPY; MOLECULARLY TARGETED THERAPY; MULTIPLE SCLEROSIS; NANODEVICE; NANOENCAPSULATION; NANOTECHNOLOGY; NANOTHERAPY; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PARTICLE SIZE; PROTEIN PURIFICATION; REGULATORY T LYMPHOCYTE; RETICULOENDOTHELIAL SYSTEM; SHORT SURVEY; SIGNAL TRANSDUCTION; SUSTAINED DRUG RELEASE; T LYMPHOCYTE ACTIVATION; TH17 CELL; THROMBOCYTOPENIA; VACCINATION; WEST NILE FEVER; WOUND HEALING;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNE DISEASES; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA INHIBITORY FACTOR; MULTIPLE SCLEROSIS; NANOMEDICINE; NANOSTRUCTURES; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; VACCINES;

HARNESS;

EID: 84856655642     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.11.002     Document Type: Short Survey

References (58)

1. Fahmy T.M., et al. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine (Lond.) 2008, 3:343-355.
2. Singh M., Srivastava I. Advances in vaccine adjuvants for infectious diseases. Curr. HIV Res. 2003, 1:309-320.
3. Sesardic D., Dobbelaer R. European union regulatory developments for new vaccine adjuvants and delivery systems. Vaccine 2004, 22:2452-2456.
4. Bramwell V.W., Perrie Y. The rational design of vaccines. Drug Discov. Today 2005, 10:1527-1534.
5. Pashine A., et al. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 2005, 11:S63-S68.
6. Lindblad E.B. Aluminium adjuvants - in retrospect and prospect. Vaccine 2004, 22:3658-3668.
7. Gupta R.K., et al. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993, 11:293-306.
8. Gupta R.K., Siber G.R. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995, 13:1263-1276.
9. Lindley M.C., et al. Financing the delivery of vaccines to children and adolescents: challenges to the current system. Pediatrics 2009, 124(Suppl. 5):S548-S557.
10. Minor P.D., et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009, 27:2907-2913.
11. Glass R.I., et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006, 368:323-332.
12. Rodriguez-Chavez I.R., et al. Current advances and challenges in HIV-1 vaccines. Curr. HIV/AIDS Rep. 2006, 3:39-47.
13. Mellman I. Antigen processing and presentation by dendritic cells: cell biological mechanisms. Adv. Exp. Med. Biol. 2005, 560:63-67.
14. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
15. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
16. Steinman R.M., Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top Microbiol. Immunol. 2006, 311:17-58.
17. Demento S.L., et al. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol. 2011, 29:294-306.
18. Schuler G., et al. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 2003, 15:138-147.
19. Morelli A., Thomson A. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat. Rev. Immunol. 2007, 7:610-621.
20. Lu L., Thomson A.W. Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation 2002, 73(Suppl. 1):S19-S22.
21. Taner T., et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival. Am. J. Transplant. 2005, 5:228-236.
22. Turnquist H.R., et al. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 2007, 178:7018-7031.
23. McMahon G., et al. The evolving role of mTOR inhibition in transplantation tolerance. J. Am. Soc. Nephrol. 2011, 22:408-415.
24. Haddadi A., et al. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. J. Biomed. Mater. Res. A. 2008, 84A:885-898.
25. Look M., et al. Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival. Am. J. Transplant. 2011, 10.1111/j.1600-6143.2011.03725.x.
26. Ziegler S.F., Buckner J.H. FOXP3 and the regulation of Treg/Th17 differentiation. Microbes Infect. 2009, 11:594-598.
27. Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010, 140:845-858.
28. Mendez S., et al. Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J. Exp. Med. 2004, 200:201-210.
29. McCarthy N. Immunotherapy: suppressing regulatory T cells. Nat. Rev. Cancer 2006, 6:6.
30. Metcalfe S.M., et al. Leukemia inhibitory factor is linked to regulatory transplantation tolerance. Transplantation 2005, 79:726-730.
31. Niwa H., et al. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature 2009, 460:118-122.
32. Gao W., et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle 2009, 8:1444-1450.
33. Metcalfe, S.M. and De S Muthukumarana, P.A. (2005) Transplantation tolerance: gene expression profiles comparing allotolerance vs. allorejection. Int. Immunopharmacol. 5, 33-39.
34. Metcalfe S.M., et al. Leukaemia inhibitory factor (LIF) is functionally linked to axotrophin and both LIF and axotrophin are linked to regulatory immune tolerance. FEBS Lett. 2005, 579:609-614.
35. Alberti K., et al. Functional immobilization of signaling proteins enables control of stem cell fate. Nat. Methods 2008, 5:645-650.
36. Park J., et al. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol. Pharm. 2011, 8:143-152.
37. Oliveira V.G., et al. Sub-optimal CD4+ T-cell activation triggers autonomous TGF-beta-dependent conversion to Foxp3+ regulatory T cells. Eur. J. Immunol. 2011, 41:1249-1255.
38. Shi L.Z., et al. HIF1{alpha}-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 2011, 208:1367-1376.
39. Walter J. An epigenetic Tet a Tet with pluripotency. Cell Stem Cell 2011, 8:121-122.
40. Lorsbach R.B., et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17:637-641.
41. Blanchard F., et al. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Oncogene 2002, 21:6264-6277.
42. Cobb B.S., et al. A role for Dicer in immune regulation. J. Exp. Med. 2006, 203:2519-2527.
43. Stockinger B., Veldhoen M. Differentiation and function of Th17 T cells. Curr. Opin. Immunol. 2007, 19:281-286.
44. Chen X., et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009, 114:891-900.
45. Powell J.D., Delgoffe G.M. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010, 33:301-311.
46. Metcalfe S.M. Axotrophin and leukaemia inhibitory factor (LIF) in transplantation tolerance. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2005, 360:1687-1694.
47. Thompson L.H., et al. A LIF/Nanog axis is revealed in T lymphocytes that lack MARCH-7, a RINGv E3 ligase that regulates the LIF-receptor. Cell Cycle 2010, 9:4213-4221.
48. Bettelli E., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
49. Jeong C.H., et al. Hypoxia-inducible factor-1 alpha inhibits self-renewal of mouse embryonic stem cells in vitro via negative regulation of the leukemia inhibitory factor-STAT3 pathway. J. Biol. Chem. 2007, 282:13672-13679.
50. Nilsson C.L., et al. Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J. Proteome Res. 2010, 9:430-443.
51. Wang J.H., et al. Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome Med. 2011, 3:3.
52. Bauer S., et al. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat. Rev. Neurosci. 2007, 8:221-232.
53. Slaets H., et al. Therapeutic potential of LIF in multiple sclerosis. Trends Mol. Med. 2010, 16:493-500.
54. Metcalfe S.M. LIF in the regulation of T-cell fate and as a potential therapeutic. Genes Immun. 2011, 12:157-168.
55. Cao W., et al. Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity 2011, 35:273-284.
56. Metcalfe S.M. Multiple sclerosis: one protein, two healing properties. Nature 2011, 477:287-288.
57. Jones J.L., et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010, 133:2232-2247.
58. Muthukumarana P., et al. Regulatory transplantation tolerance and " stemness" : evidence that Foxp3 may play a regulatory role in SOCS-3 gene transcription. Transplantation 2007, 84(Suppl. 1):S6-S11.